InsiderSource
ZYME

Zymeworks Inc.

SEC CIK 1937653
$23.14 +1.8% · 90 days
90-day buys
$0
0 open-market
90-day sells
$0
0 open-market
Net insider flow
+$0
Net buying
Filings shown
26
Most recent
Advertisement

At a glance

Insiders at ZYME have made no open-market trades in the last 90 days — the activity below is grants, option exercises, and other routine filings.

Largest recent trade: Galbraith Kenneth sold $1.28M of ZYME, trimming their stake 26%.

Most active filer: Galbraith Kenneth, with 7 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for ZYME, newest first
View on SEC EDGAR ↗
ZYME
Zymeworks Inc.
Option exercise Hollywood Mark · EVP & Chief Operating Officer · Option exercise · filed Jan 13, 2026 ΔOwn +15%
+$0
17,666 sh
ZYME
Zymeworks Inc.
Sell Hollywood Mark · EVP & Chief Operating Officer · Open-market sale · filed Jan 13, 2026 ΔOwn −4.4%

Hollywood Mark sold $138.8K of ZYME, trimming their stake 4%.

−$138.8K
6,120 sh @ $23
ZYME
Zymeworks Inc.
Sell Smith Jeffrey T L · EVP & Chief Medical Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −26%

Smith Jeffrey T L sold $211.1K of ZYME, trimming their stake 26%.

−$211.1K
9,310 sh @ $23
Advertisement
ZYME
Zymeworks Inc.
Sell Moore Paul Andrew · Chief Scientific Officer · Open-market sale · filed Jan 12, 2026 ΔOwn −16%

Moore Paul Andrew sold $216.8K of ZYME, trimming their stake 16%.

−$216.8K
9,560 sh @ $23
ZYME
Zymeworks Inc.
Sell Galbraith Kenneth · Director, Chair & CEO · Open-market sale · filed Jan 12, 2026 ΔOwn −12%

Galbraith Kenneth sold $689.8K of ZYME, trimming their stake 12%.

−$689.8K
30,424 sh @ $23
ZYME
Zymeworks Inc.
Sell Smith Jeffrey T L · EVP & Chief Medical Officer · Open-market sale · filed Jan 5, 2026 ΔOwn −36%

Smith Jeffrey T L sold $264.5K of ZYME, trimming their stake 36%.

−$264.5K
10,538 sh @ $25
ZYME
Zymeworks Inc.
Sell Galbraith Kenneth · Director, Chair & CEO · Open-market sale · filed Jan 5, 2026 ΔOwn −13%

Galbraith Kenneth sold $568.6K of ZYME, trimming their stake 13%.

−$568.6K
22,657 sh @ $25
ZYME
Zymeworks Inc.
Sell Galbraith Kenneth · Director, Chair & CEO · Open-market sale · filed Jan 5, 2026 ΔOwn −14%

Galbraith Kenneth sold $795.2K of ZYME, trimming their stake 14%.

−$795.2K
31,686 sh @ $25
ZYME
Zymeworks Inc.
Sell Moore Paul Andrew · Chief Scientific Officer · Open-market sale · filed Jan 5, 2026 ΔOwn −23%

Moore Paul Andrew sold $233.1K of ZYME, trimming their stake 23%.

−$233.1K
9,289 sh @ $25
ZYME
Zymeworks Inc.
Sell Moore Paul Andrew · Chief Scientific Officer · Open-market sale · filed Jan 5, 2026 ΔOwn −21%

Moore Paul Andrew sold $271.6K of ZYME, trimming their stake 21%.

−$271.6K
10,821 sh @ $25
ZYME
Zymeworks Inc.
Sell Galbraith Kenneth · Director, Chair & CEO · Open-market sale · filed Dec 22, 2025 ΔOwn −26%

Galbraith Kenneth sold $1.28M of ZYME, trimming their stake 26%.

−$1.28M
47,528 sh @ $27
ZYME
Zymeworks Inc.
Buy EcoR1 Capital, LLC · Director, 10% Owner · Open-market purchase · filed May 19, 2025

Ecor1 Capital, Llc, ZYME's 10% owner, spent $69.7K of their own money on 5,919 shares at $12.

+$69.7K
5,919 sh @ $12
ZYME
Zymeworks Inc.
Buy EcoR1 Capital, LLC · Director, 10% Owner · Open-market purchase · filed May 19, 2025 ΔOwn +0.3%

Ecor1 Capital, Llc, ZYME's 10% owner, spent $565.8K of their own money on 49,502 shares at $11.

+$565.8K
49,502 sh @ $11
ZYME
Zymeworks Inc.
Buy EcoR1 Capital, LLC · Director, 10% Owner · Open-market purchase · filed Apr 18, 2025 ΔOwn +0.3%

Ecor1 Capital, Llc, ZYME's 10% owner, spent $630.8K of their own money on 54,760 shares at $12.

+$630.8K
54,760 sh @ $12
ZYME
Zymeworks Inc.
Buy EcoR1 Capital, LLC · Director, 10% Owner · Open-market purchase · filed Apr 18, 2025 ΔOwn +0.4%

Ecor1 Capital, Llc, ZYME's 10% owner, spent $825.6K of their own money on 73,953 shares at $11.

+$825.6K
73,953 sh @ $11
Advertisement

About ZYME insider activity

This page tracks every recent Form 4 filed for Zymeworks Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is ZYME insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Zymeworks Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.